BioNTech SE (FRA:22UA)
Germany · Delayed Price · Currency is EUR | Market Cap | 18.98B |
| Revenue (ttm) | 3.15B |
| Net Income (ttm) | -571.60M |
| Shares Out | n/a |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,215 |
| Average Volume | 2,107 |
| Open | 78.50 |
| Previous Close | 79.00 |
| Day's Range | 77.95 - 80.00 |
| 52-Week Range | 71.00 - 124.60 |
| Beta | n/a |
| RSI | 40.70 |
| Earnings Date | Mar 10, 2026 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
Noteworthy ETF Inflows: FNDF, APTV, BNTX, NXPI
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab Fundamental International Large Company Index (Symbol: FNDF) wh...
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3%...
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co. (NYSE: BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherap...
BioNTech, Bristol-Myers Squibb Announce Interim Results From Pumitamig Study
(RTTNews) - BioNTech SE (BNTX) and Bristol-Myers Squibb Company (BMY), Tuesday announced the first interim data from a global randomized Phase 2 trial, evaluating pumitamig in patients with locally ad...
BioNTech SE: BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer ("TNBC") show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus c...
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chem...
BioNTech (BNTX) Sees Promising Survival Data in Lung Cancer Trial
BioNTech (BNTX) Sees Promising Survival Data in Lung Cancer Trial
BioNTech SE: BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the firs...
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC
BioNTech Secures Majority Of CureVac Shares As Exchange Offer Advances
(RTTNews) - BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
BioNTech (BNTX) Advances with CureVac Acquisition
BioNTech (BNTX) Advances with CureVac Acquisition
BioNTech SE: BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expir...
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati...
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths
Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.
BioNTech (BNTX) Q3 2025 Earnings Call Transcript
BioNTech (BNTX) Q3 2025 Earnings Call Transcript
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3
Understood! Please provide the article or its content so I can generate the SEO-friendly meta description.
BioNTech SE: BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
Offer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.E...
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
MAINZ, Germany, November 26, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the approval of matters relating to the exchange offer (the “Offer”) for all outstanding shares of CureVac N....
CureVac Reveals Key Voting Outcomes from Extraordinary Shareholder Meeting
CureVac’s latest Extraordinary General Meeting delivered near-unanimous backing for BioNTech’s exchange offer and key merger decisions, reshaping the company’s future.
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations